Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: